Presseinformationen weltweit an Journalisten und Leser verbreiten
Bavarian Nordic A/S (OMX: BAVA) announced today its interim financial results for the first nine months of 2023 and business progress for the third quarter of 2023. Revenue for the first nine months increased by 148% to DKK 4,615 million Mehr
Bavarian Nordic A/S (OMX: BAVA) will announce its 2023 third quarter results on Thursday, November 16, 2023. The management of Bavarian Nordic will host a conference call at 2:00 pm CET (8:00 am EST) on the same day to present Mehr
Bavarian Nordic A/S (OMX: BAVA) announced today, that it has been awarded another contract valued at more than EUR 11 million to supply its MVA-BN® smallpox vaccine to rescEU, a strategic reserve within the European Union (EU). This order follows an Mehr
Contract award will support manufacturing of new bulk vaccine to partly replenish the inventory used for the mpox outbreak in 2022 Aims to strengthen the long-term U.S. stockpiling of smallpox vaccines Company upgrades its financial guidance for 2023 Bavarian Mehr
Bavarian Nordic A/S (OMX: BAVA) today published its Annual Report for 2022. The consolidated, audited results were in line with the preliminary results, announced on January 16, 2023. The full report is attached as a PDF file and can be Mehr
First subject vaccinated in Phase 3 clinical trial evaluating potential of the VLP-based candidate, ABNCoV2 as a booster COVID-19 vaccine Trial will assess non-inferiority of ABNCoV2 compared to Comirnaty® in terms of neutralizing antibodies against the SARS-CoV-2 (Wuhan wild type) Mehr
A number of contracts of varying size have been signed Deliveries to start immediately aiming to ensure a rapid response to the current monkeypox outbreak Company upgrades its financial guidance for 2022 Bavarian Nordic A/S (OMX: BAVA) announced today Mehr